Two articles recently appeared in *ACS Chemical Neuroscience* that need attention.^[@ref1],[@ref2]^ The article published by Bilinska et al. indicated that sustentacular cells are responsible for Severe Acute Respiratory Syndrome (SARS)-like Coronavirus (SARS-CoV-2) entry and related smell impairment.^[@ref1]^ Bilinska et al. also reported that non-neuronal cells of the olfactory epithelium (OE) are more likely to be the entry point of SARS-CoV-2 virus rather than olfactory receptor neurons (ORNs).^[@ref1]^ In the second report, Butowt and Bilinska highlighted the need for OE-oriented experimental studies to clarify various points related to SARS-CoV-2 virus and the continuous need for clinical data related to SARS-CoV-2 and related smell loss.^[@ref2]^

Brann et al. reported that direct involvement of olfactory sensory neurons (OSNs) may not occur in SARS-CoV-2 infection since OSNs did not express ACE2. Non-neural cell types (e.g., stem cells, TMPRSS2 support cells, and perivascular cells) express ACE2, and they are responsible for related smell impairment.^[@ref3]^ Brann et al. hypothesized that inflammation, deteriorated signaling, and diffuse architectural damage of the OE may be the mechanisms for smell impairment.

On the basis of these experimental studies, in the clinical setting smell impairment needs to be resolved early and spontaneously because in the majority of the cases direct involvement of OSNs did not widely occur. In order to evaluate the consistency between experimental and clinical findings, we systematically reviewed clinical studies that reported resolution rates in SARS-CoV-2-related smell impairment.^[@ref4]−[@ref14]^

The results are presented in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. Published studies indicated that smell impairment in SAR-CoV-2 recovered early. At present, no treatment for SARS-CoV-2-related smell impairment exists. In two studies, some treatments, including nasal saline irrigation, intranasal corticosteroids, systemic corticosteroids, dietary supplements, vitamin A, and olfactory training, on limited number of the subjects were reported.^[@ref7],[@ref11]^ However, no definite conclusion could be made concerning the effect of treatment on recovery rates. Smell loss mostly recovered in a few weeks after the infection and seemed to reduce with time.

###### Summary of Studies of SARS-COV-2-Related Smell/Taste Impairment That Reported Recovery Dynamics[a](#t1fn1){ref-type="table-fn"}

  authors                              design                                                                                     number of subjects                                                                              test method                          smell/taste impairment rate                                                                                           recovery characteristics
  ------------------------------------ ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------- ------------------------------------ --------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sayin et al.^[@ref4]^                comparative between COVID-19 (+) and COVID-19 (−) subjects                                 64 COVID-19 (+) subjects compared with 64 COVID-19 (−) subjects                                 RT-PCR                               71.9% for the COVID-19 (+) group vs 26.6% for the COVID-19 (−) group                                                  45.7% for COVID-19 (+) subjects and 64.7% for COVID-19 (−) subjects at the time of the study
  Lee et al.^[@ref5]^                  single-arm descriptive                                                                     3191 COVID-19 subjects                                                                          NS                                   15.3% (*n* = 488)                                                                                                     the median time to recovery from anosmia and ageuisa was 7 days,[b](#t1fn3){ref-type="table-fn"} and most of the subjects recovered in 3 weeks
  Paderno et al.^[@ref6]^              comparative between COVID-19 (+) hospitalized and COVID-19 (+) home-quarantined subjects   508 subjects (295 hospitalized and 213 home-quarantined)                                        RT-PCR                               overall OD and GD were present in 56% and 63% of the subjects                                                         complete resolution of OD and GD was 52% and 55% at the time of the questionnaire; mean RT was9 ± 5 days
  Hopkins et al.^[@ref7]^              single-arm descriptive                                                                     382 subjects underwent an initial survey and a follow-up survey 1 week after the first survey   NS[c](#t1fn4){ref-type="table-fn"}   overall 97.9% smell impairment rate                                                                                   80.1% of subjects reported improvement in smell impairment in 1 week (recovery appearing to plateau after 3 weeks)
  Kaye et al.^[@ref8]^                 single-arm descriptive                                                                     237 subjects                                                                                    NS                                   100%[d](#t1fn5){ref-type="table-fn"}                                                                                  some improvement on 27% of the subjects (mean improvement time 7.2 days)
  Beltrán-Corbellini et al.^[@ref9]^   comparative between COVID-19 (+) and influenza (+) subjects                                70 COVID-19 (+) and 40 influenza (+) subjects                                                   RT-PCR                               39.2% for COVID-19 (+) and 12.5% for influenza (+) subjects                                                           40% complete recovery after 7.4 ± 2.3 days and 16.7% partial recovery after 9.1 ± 3.6 days. For influenza (+) subjects, 100% recovered
  Yan et al.^[@ref10]^                 comparative between COVID-19 (+) and COVID-19 (−) subjects                                 59 COVID-19 (+) subjects compared with 203 COVID (−) subjects                                   RT-PCR                               smell and taste loss were reported in 68% and 71% of COVID-19 (+) subjects and 16% and 17% of COVID-19 (−) subjects   74% reported resolution of anosmia with clinical resolution of illness; RT was noted as less than 2 weeks; GD: NS
  Lechien et al.^[@ref11]^             single-arm descriptive                                                                     417 subjects                                                                                    RT-PCR                               85.6% reported OD and 88.0% GD                                                                                        early olfactory RT was 44.0%; GD: NS
  Klopfenstein et al.^[@ref12]^        single-arm descriptive                                                                     114 subjects                                                                                    RT-PCR                               47.3% OD and 40.3% GD                                                                                                 98% subjects with anosmia improved in 28 days; GD: NS
  Dell'Era et al.^[@ref13]^            single-arm descriptive                                                                     355 subjects                                                                                    RT-PCR                               66% for OD and 65.4% for GD                                                                                           62.9% of subjects with OD fully recovered at the time of the survey (median RT 10 days, range 1--25 days), and 63.8% of subjects with GD fully recovered at the time of the survey (median RT 10 days, range 2--25 days)
  Vaira et al.^[@ref14]^               single-arm descriptive                                                                     345 subjects underwent objective chemosensitive evaluation                                      RT-PCR                               65% for OD and 67.8% for GD                                                                                           complete resolution for OD and GD were 31.3% and 50.4%, respectively, at the time of the study; improvement was evident in the first and second weeks of disease

Abbreviations: RT-PCR, real-time polymerase chain reaction; NS, not specified; OD, olfactory dysfunction; GD, gustatory dysfunction; RT, recovery time.

Percentage not specified in the manuscript.

Some subjects were tested, but there was a lack of confirmed COVID-19 status.

The American Academy of Otolaryngology---Head and Neck Surgery Anosmia Reporting Tool was used, and only subjects with anosmia completed the tool.

The present report has some limitations. This report's knowledge was limited to published data to date. The reviewed articles were mostly observational and questionnaire-based. Among the rewieved articles for this report; only one study used objective testing methods and reported outcomes.^[@ref14]^ Literature data point out that there will be an inconsistency between patient-reported and objective-testing-determined smell/taste impairment. However, nasal procedures, detailed examinations, and close contact with subjects were avoided during the pandemic, which resulted in a limited number of studies that reported objective outcomes. Besides, the studies regarding smell/taste impairment were mostly cross-sectional single-arm studies. Comparative studies with SARS-CoV-2 (−) subjects and comparative studies with other upper respiratory tract infection causes were limited in number. Even for the studies that presented followup, the followup period was limited to weeks. Larger studies with objective testing methods and longer followup periods will deepen our knowledge about SARS-CoV-2-related taste/smell impairment.

These findings represent a well-linked relation between experimental studies and clinical studies. Experimental researchers may use these data to observe the dynamics of smell impairment and implement these findings in their researches (e.g., correct timing of sampling) to perform further studies.
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